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Abstract: Cancer-associated malnutrition, or cachexia, stemming from cancer or its treatments, is
particularly prevalent in metastatic cancers, and is often interrelated with sarcopenia and frailty.
Evidence suggests that dietary supplements play a role in managing these conditions. As metastatic
cancer cells are associated with notable genomic and phenotypic alterations, response to dietary
supplements may differ between metastatic and non-metastatic cancers. However, research in this
area is lacking. This scoping review aims to identify the dietary supplements that have been studied
in patients with metastatic cancers and malnutrition-related conditions, along with their proposed
effects, mechanisms, outcome measures, and tools used. A systematic search was conducted across
databases, including MEDLINE, EMBASE, CINAHL, and clinical trial registries. Of the initial
6535 records screened, a total of 48 studies were included, covering a range of dietary supplements—
vitamins, minerals, antioxidants, proteins, amino acids, fatty acids, fiber, and others. While the types
of dietary supplements included varied across cancer types, omega-3 and carnitine were investigated
most often. Proposed relevant attributes of dietary supplements included their antioxidant, antiinflammatory, anti-cancer, and immunomodulatory properties. Overall, there was a paucity of
interventional studies, and more randomized controlled trials are warranted.
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1. Introduction
Cancer treatments have significantly improved over time, leading to a prolonged
survival time after a diagnosis of metastatic cancer, and consequently an increased number of advanced cancer survivors [1]. Advanced cancer survivors experience a range of
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complications arising from cancer, its treatments, and metabolic derangements [2–7]. Dietrelated unmet care needs, including a lack of appetite and gastrointestinal symptoms, are
commonly reported among people with metastatic cancers [8].
Malnutrition, cachexia, and sarcopenia are highly prevalent in people with metastatic
cancer. Approximately half of people with metastatic cancer are reported to be moderately
to severely malnourished [9,10], and almost all require some form of nutritional intervention [9]. Cancer-associated malnutrition, or cachexia, is a weight loss syndrome involving
systemic inflammation and complex metabolic processes, often due to reduced nutritional
intake owing to cancer-related side effects [11,12]. Sarcopenia is defined by the presence of
low muscle strength, low muscle quantity and quality, and poor physical performance [13].
Sarcopenia is frequently observed in people with metastatic cancer and is associated with
poorer prognosis and outcomes, as compared to those without [14–16]. Meanwhile, frailty is
increasingly recognized as a critical health issue in people with metastatic cancer [17]. This
state of vulnerability can be a culmination of aging, life prolonging cancer treatments, and
cancer itself, and is an independent predictor of mortality [18,19]. Malnutrition, cachexia,
sarcopenia, and frailty exhibit phenotypically similar features that are interrelated [20].
Modifications to diet, such as the use of dietary supplements, can alleviate cancerassociated symptoms [21] and, at times, enhance the efficacy of cancer treatments [22].
Dietary supplements are defined as concentrated sources of nutrients or other ingredients
with a nutritional or physiological effect [23]. These include vitamins, minerals, botanicals
or herb extracts, amino acids, essential fatty acids, and fiber [23,24]. Although there
are a lack of clinical guidelines or consistent recommendations for the use of dietary
supplements in people with metastatic cancer, dietary supplements are reportedly used
by cancer survivors with the intention of improving symptoms and outcomes [25,26]. A
previous systematic review investigating the role of vitamins, minerals, proteins, and other
supplements for the treatment of cancer cachexia reported insufficient evidence advocating
for the use of dietary supplements in people with cancer [27]. However, the review did
not include younger people or people with malnutrition-related conditions other than
cachexia (e.g., sarcopenia and frailty), and inclusion criteria were limited to cancer survivors
with cachexia who may not necessarily have metastatic cancer. As metastatic cancer cells
are associated with significant genomic and phenotypic alterations, responses of people
with metastatic cancer to dietary supplements may differ from people with non-metastatic
cancer and earlier stages of disease [2]. There is currently a lack of evidence synthesis that
has systematically explored different dietary supplements that have been used in studies
conducted in people with metastatic cancer and malnutrition-related syndromes (e.g.,
cachexia, sarcopenia, and frailty).
To address this gap, the primary aim of this scoping review was to systematically
map out the body of evidence regarding dietary supplements administered orally or
enterally in patients with metastatic cancers and malnutrition-related syndromes, including
their hypothesized effects, proposed mechanisms, as well as outcome measures (and
corresponding tools) used to evaluate their effects.
2. Materials and Methods
2.1. Protocol and Registration
The scoping review was conducted using a systematic approach, following the JBI
methodology for scoping reviews [28], and is reported in accordance with the Preferred
Reporting Items for Systematic reviews and Meta-analyses extension for Scoping Reviews
(PRISMA-ScR) Checklist [29] (Supplementary File S1). A preliminary search for previous
scoping reviews and systematic reviews on the topic was conducted in Medline via PubMed
on 5 December 2021.
2.2. Aims and Methodology
The aims and method for this review were prospectively documented in the Open
Science Framework Registry (https://osf.io/g483m, accessed on 5 April 2022). The search
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strategy was developed by two authors (JJ and CH) and a review, consisting of keywords and
controlled vocabulary terms, was conducted by a research librarian (Supplementary File S2).
A search was conducted across seven included electronic databases (MEDLINE, EMBASE,
CINAHL, Cochrane CENTRAL, JBI Evidence Synthesis, Scopus, and Web of Science) and
clinical trial registries (ISRCTN registry, clinicaltrials.gov, and World Health Organization
International Clinical Trials Registry) on 5 February 2022. Sources that were published in
English were included. To provide a comprehensive map of the literature, no restrictions
were placed on the publication dates of sources. The sources yielded from the search
were imported into the Covidence software [30], where duplicates were removed by
the software and confirmed by two researchers in the study. Screening and selection
of articles were conducted independently by two authors via Covidence [30] using the
study inclusion and exclusion criteria (Table 1). Discrepancies regarding the inclusion
of articles were resolved via consensus. In this study, dietary supplements were defined
as vitamins, minerals, proteins/amino acids, fatty acids, prebiotics/fiber, probiotics, and
plant/herbal extracts, while oral nutrition supplements (ONS) were defined as liquid-based
unenriched or unfortified energy-protein formulations. In line with the definition of ‘dietary
supplements’ [31], only supplements which were delivered orally were considered. This
was extended to include enteral routes to account for people who require tube feeding.
While it was recognized that people with metastatic cancers may require alternate routes of
delivery (e.g., intravenous or intramuscular), these were not included, as these absorption
pathways (and subsequently, required doses) differ from that of oral administration.
Table 1. List of inclusion and exclusion criteria.
Inclusion Criteria
Human studies
Primary, quantitative studies, or systematic reviews

Studies investigating the effects of dietary supplements
(vitamins, minerals, proteins or amino acids, fatty acids,
prebiotics or fiber, probiotics, and plant or herbal extracts)
whether in isolation or in combination with other dietary
supplements or interventions
Studies conducted among people with metastatic cancer
(defined as Stage IV)

Studies including people with malnutrition cachexia or
anorexia, sarcopenia, frailty, or weight loss

Additional Operational Information
Systematic reviews are defined as reviews with a
comprehensive search strategy, methods section, and critical
appraisal of included studies
This includes studies where dietary supplements were not the
intervention of interest or all study groups received the same
dietary supplements, as intra-group comparisons may have
been made, which can provide information on the effects of
dietary supplements.
This is further defined by the following cut-off values: for
primary trials, at least 50% metastatic; for systematic reviews, at
least 50% included papers conducted in solely metastatic
populations; for studies yet to be completed, only those that set
out to recruit solely patients with metastatic cancers.
Studies that consisted of a subset of patients (any proportion)
with these conditions were included. Nutrient deficiencies were
also considered a form of malnutrition. If the nutrition status of
study participants was not specified, articles were considered to
meet the inclusion criteria regarding malnutrition-related
conditions as long as they meet the earlier criteria of metastatic
cancer, as it has been established in the literature that
malnutrition is prevalent in people with advanced cancer [32].

Exclusion Criteria
Animal or laboratory studies
Qualitative studies or narrative/literature reviews
Studies investigating the effects of drugs or traditional medicine (e.g., Chinese herbal therapies)
Supplements administered via intravenous or intramuscular routes (e.g., intravenous ascorbic acid infusion)
Studies investigating the effect of oral nutritional supplements alone, which have not been enhanced with dietary supplement(s) of
interest (e.g., unfortified standard formulations of commercial milk-based supplements, such as Ensure® )

Where there was missing information that precluded a decision on the inclusion
or exclusion of the article, corresponding authors of the article were emailed to retrieve
more information. Data extraction was performed jointly by two authors (JJ and CH)
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using a data extraction form (Supplementary File S3) that was developed by the team
and pilot tested by the same two authors (JJ and CH) prior to use to ensure all relevant
results were extracted. Extracted data were subsequently reviewed by another author
(RJ). Data extraction included information on the dietary supplements that have been
investigated in the target population, as well as their hypothesized effects and proposed
mechanisms, and outcome measures that have been assessed. In line with the purpose
of scoping reviews outlined in the literature, the present scoping review was intended to
map and summarize available evidence, without investigating effectiveness or formulating
recommendations for clinical practice [33]. Hence, findings on the actual outcomes of the
included studies were not analyzed. Findings of interest to the present scoping review
(supplement types, hypothesized effects, proposed mechanisms, and outcome measures
used) were narratively synthesized.
3. Results
3.1. Search Results
The initial search yielded 8070 records from the databases, 227 records from the clinical
trial registries, and 3 records from other sources (Figure 1). After removal of duplicates,
6535 records remained, of which 6286 were excluded following title and abstract screening.
Of the 248 full-text articles assessed for eligibility, 200 were excluded. A total of 48 articles
met the criteria and were included in narrative synthesis.

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA 2020)
flow diagram.
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3.2. Study Characteristics
The 48 articles were classified into the following categories: full text peer-reviewed
manuscripts (n = 38), conference abstracts (n = 8), and clinical trial registrations (n = 2). Of
the full text peer-reviewed manuscripts, the majority reported on randomized controlled
trials (RCTs) (n = 18) [34–51], followed by quasi-experimental trials (n = 15) [52–66], retrospective cohort observational studies (n = 2) [67,68], and case studies (n = 3) [69–71]. Conference abstracts reported on RCTs (n = 3) [72–74], quasi-experimental trials (n = 4) [75–78],
and a case study (n = 1) [79]. The two clinical trial registrations consisted of one RCT [80],
which was terminated as sample size could not be reached, and one quasi-experimental
trial [81], which has not commenced recruitment. It was noted that two articles [42,74]
may have included the same subset of patients with gynecological cancers, though one
of the trials also included additional patients with mixed cancer types [74]. The number
of studies and the corresponding range of sample sizes across the different study types,
cancer types, and countries are all included in Table 2.
3.3. Types of Dietary Supplements
A variety of dietary supplements were investigated across studies and were grouped
into the following categories: vitamins (n = 13), minerals (n = 5), antioxidants (apart
from vitamins and minerals) (n = 7), proteins (n = 3), amino acids (n = 14), fatty acids
(n = 18), fiber (n = 1), and others (n = 5). Dietary supplements were provided orally in all
except three studies [36,67,71], where they were administered enterally. Table 3 shows the
types of dietary supplements, cancers, and malnutrition-related conditions in each of the
different studies.
3.4. Forms and Dosages
3.4.1. Vitamins, Minerals, and Other Antioxidants
Vitamins included in studies were vitamin A (n = 2) [44,54], B1 (n = 1) [76], B6 (n = 2) [70,76],
B9 (n = 4) [46,60,61,68], B12 (n = 1) [60], C (n = 2) [44,54], D (n = 4) [40,59,62,64], and E
(n = 3) [39,44,54]. Minerals included were calcium (n = 2) [62,64], iron (n = 2) [68,79],
and selenium (n = 1) [75]. Antioxidants (other than vitamins and minerals) included
carbocysteine (n = 4) [42,44,54,74], lipoic acid (n = 4) [42,44,54,74], quercetin (n = 2) [44,54],
curcumin (n = 2) [73,77], and lycopene (n = 1) [66].
The three antioxidant vitamins—Vitamins A, C, and E— were administered concomitantly as part of antioxidant treatments with the same dosages (Vitamin A 30,000 IU daily;
Vitamin C 500 mg daily; Vitamin E 400 mg daily) in two studies (an RCT [44] and a quasiexperimental single-group trial [54]) that investigated the efficacy of combined treatments
and also included other dietary supplements, such as quercetin, carbocysteine, lipioic acid,
eicosapentaenoic acid (EPA), and/or carnitine. In the RCT, all five study arms were given
the vitamins [44]. Vitamin E was additionally included in one other RCT, where it was
given to the intervention group which received fish oil as the main intervention [39].
Vitamins B1 (thiamine) and B6 (pyridoxine) were included in a quasi-experimental
trial, in the form of Aminotrofic® sachets, which mainly consisted of amino acids [76].
Vitamin B6 was additionally included in a case study as a replacement therapy in doses
of 150 mg daily [70]. Vitamin B9 (folate) was administered in an RCT [46], two quasiexperimental trials [60,61], and an observational study [68], of which all also involved
concomitant vitamin B12 administration and pemetrexed therapy. In the RCT, where
the main aim was to test the efficacy of different doses of pemetrexed, Vitamin B9 was
administered to both study groups via a daily multivitamin containing 500 mg folic acid,
along with regular intramuscular vitamin B12 [46]. In one of the quasi-experimental trials,
where the aim of the study was to test if the lead-in time for vitamin B supplementation
prior to cisplatin-pemetrexed therapy could be shortened, vitamin B9 supplementation in
doses of 350–500 µg daily were administered, along with intramuscular vitamin B12 [61].
In the other quasi-experimental trial, where the aim was to evaluate the safety of oral
administration of vitamin B12, vitamin B9 (500 µg daily) was administered along with
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vitamin B12 in patients receiving pemetrexed [60]. In the observational study, vitamin B9
was administered in doses of either 400 µg, 700 µg, or 1000 µg once daily depending on
the individual’s baseline total plasma homocysteine level, along with regular oral iron and
intramuscular vitamin B12 [68]. The latter study aimed to assess the prevalence of elevated
total plasma homocysteine levels at baseline and following pemetrexed treatment, as well
as the association between folic acid supplementation and hematological toxicity [68].
One study (a quasi-experimental trial) included vitamin B12 administered orally. The
first six participants received 500 µg vitamin B12 daily (along with vitamin B9), while
subsequent participants were treated under the updated protocol (following the findings
of a study, published then, which showed a lack of efficacy of 1000 µg vitamin B12), where
they received 2000 µg daily of vitamin B12 for seven days followed by a dose of 500 µg
daily thereafter instead [60].
Table 2. Number of completed studies (excluding one clinical trial registration which has not started
recruitment) and number of participants included, according to study type, cancer type, and country.
Study Type
Full-text article
Randomized controlled trial
Quasi-experimental trial
Retrospective cohort observational
Case study
Conference abstracts
Randomized controlled trial
Quasi-experimental trial
Case study
Clinical trial registrations
Randomized controlled trial
Cancer Type (Primary)
Breast
Colorectal
Gastrointestinal
Gynecological
Head and neck
Lung
Pancreatic
Prostate
Renal
Skin
Mixed or not specified
Country
Argentina
Australia
Canada
Croatia
Germany
Greece
India
Italy
Japan
Mexico
Netherlands
Poland
Portugal
Scotland
Spain
United States
United Kingdom

Number of Studies

Total Participants Range

18
15
2
3

22–472
12–144
111–135
1

3
4
1

50–127
12–36
1

1

13

1
3
1
1
4
8
4
3
2
1
19

11
13–72
128
104
1–135
22–225
1–72
13–51
12–33
1
12–472

1
1
2
1
3
1
1
12
8
1
1
1
1
1
2
8
2

22
23
23–144
72
31–72
60
111
1–332
1–225
92
32
1–51
1
26
13–135
1–472
38–46
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Table 3. Types of dietary supplements, cancers, and malnutrition-related conditions included in each of the studies.

Full-Text Article
RCT
Araki 2019 [34]
UMIN000020152
Phase NS
Berk 2008 [35]
Trial no. NS
Phase III
Buijs 2010 [36]
Trial no. and phase NS
Cerchietti 2007 [37]
Trial no. and phase NS
Cereda 2019 [38]
NCT02065726
Phase NS
Gogos 1998 [39]
Trial no. and phase NS
Golubić 2018 [40]
Trial no. and phase NS
Kraft 2012 [41]
NCT01330823
Phase NS

Nucleotides

Royal Jelly

Muscadine Grape Extract

Coenzyme Q10

BHB

Fiber

EPA ± DHA

Weight loss

HMB

PanC

FA Fr Others

Glutamine

Vitamin D
insufficiency

Carnitine

COL

BCAA

Malnutrition

Arginine

Mixed

Essential amino acids

Malnutrition

Whey protein isolate

Mixed

Lactoferrin

ProteinsAmino Acids

Quercetin

Cachexia,
anorexia

Lycopene

Lung

Lipoic acid

X

Curcumin

Antioxidants

Carbocysteine

Malnutrition

Selenium

HN

Iron

X

Calcium

Weight loss

Vitamin E

Mixed

Vitamin D

NS

Vitamin C

Renal

Vitamin B12

Minerals

Vitamin B9

Vitamins

Vitamin B6

Conditions

Vitamin A

Cancer

Vitamin B1

Author/
Year
Trial No./
Clinical Trial Phase

X

X

X

X
X
X

X

X
X
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Table 3. Cont.

Maccio 2012 [42]
Trial no. NS
Phase III
Maccio 2010 [43]
Trial no. and phase NS
Mantovani 2010 [44]
Trial no. NS
Phase III
May 2002 [45]
Trial no. and phase NS
Ohe 2008 [46]
Trial no. NS
Phase II
Pratt 2002 [47]
Trial no. and phase NS
Sanchez-Lara 2014 [48]
NCT01048970
Phase NS
Shirai 2017 [49]
Trial no. and phase NS
Solheim 2017 [50]
NCT01419145
Phase II

X

X

X

X

X
X

X
X

X

X

Nucleotides

Royal Jelly

X

X

Muscadine Grape Extract

Cachexia

X

Coenzyme Q10

Mixed

X

BHB

X

X

Fiber

NS

EPA ± DHA

GI

HMB

FA Fr Others

Glutamine

X

Carnitine

Malnutrition, weight
loss

X

BCAA

Lung

Arginine

X

Essential amino acids

Anorexia, weight
loss

Whey protein isolate

Mixed

Lactoferrin

ProteinsAmino Acids

Quercetin

NS

Lycopene

Lung

Lipoic acid

Weight loss

X

Curcumin

Antioxidants

Carbocysteine

Mixed

Selenium

Cachexia

Iron

Mixed

Calcium

Anemia

Vitamin E

Mixed

Vitamin D

Weight loss

Vitamin C

GYN

Vitamin B12

Minerals

Vitamin B9

Vitamins

Vitamin B6

Conditions

Vitamin A

Cancer

Vitamin B1

Author/
Year
Trial No./
Clinical Trial Phase
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Table 3. Cont.

Maccio 2012 [42]
Trial no. NS
Phase III
Ueno 2022 [51]
UMIN000003658
Phase II
Quasi-experimental trial
Bitting 2021 [52]
NCT02583269
Phase I
Gramignano 2006 [53]
Trial no. and phase NS
Mantovani 2006 [54]
Trial no. NS
Phase II
Murphy 2011 [55]
Trial no. NS
Phase I
Naito 2019 [56]
UMIN000023207
Phase NS

X

X

X

X
X
X

X

X

X

X

X

X

X

X

X

X

Nucleotides

Royal Jelly

Muscadine Grape Extract

Coenzyme Q10

BHB

Fiber

EPA ± DHA

HMB

FA Fr Others

Glutamine

Carnitine

BCAA

Arginine

Essential amino acids

Whey protein isolate

Lactoferrin

Cachexia,
muscle/weight loss

ProteinsAmino Acids

Quercetin

Mixed

Lycopene

Weight loss

Lipoic acid

Lung

X

Curcumin

Weight loss

Antioxidants

Carbocysteine

Mixed

Selenium

NS

Iron

Mixed

Calcium

NS

Vitamin E

Mixed

Vitamin D

Cachexia

Vitamin C

PanC

Vitamin B12

Weight loss

Minerals

Vitamin B9

GYN

Vitamins

Vitamin B6

Conditions

Vitamin A

Cancer

Vitamin B1

Author/
Year
Trial No./
Clinical Trial Phase
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Table 3. Cont.

X

X

X

X

X
X

X

X

Nucleotides

Royal Jelly

Muscadine Grape Extract

Coenzyme Q10

BHB

X

Fiber

X

EPA ± DHA

FA Fr Others

HMB

Carnitine

Vitamin D
insufficiency

X

BCAA

Prostate

Arginine

Cachexia

Essential amino acids

Mixed

Whey protein isolate

NS

Lactoferrin

ProST

ProteinsAmino Acids

Quercetin

X

Lycopene

NS

Lipoic acid

Lung

Curcumin

X

Carbocysteine

NS

Selenium

Lung

Iron

Vitamin D
insufficiency

Calcium

Breast

Vitamin E

Malnutrition

Vitamin D

COL

Vitamin C

Cachexia

Vitamin B12

Lung

Antioxidants

Glutamine

Pascoe 2021 [57]
ISRCTN39911673
Phase II
Read 2007 [58]
Trial no. NS
Phase II
Sheean 2021 [59]
NCT02186015
Phase I
Takagi 2016 [60]
UMIN000003180
Phase II
Takagi 2014 [61]
UMIN000006546
Phase II
Talalaj 2005 [62]
Trial no. and phase NS
Taylor 2010 [63]
Trial no. and phase NS
Van Veldhuizen 2000 [64]
Trial no. NS
Phase II

Minerals

Vitamin B9

Vitamins

Vitamin B6

Conditions

Vitamin A

Cancer

Vitamin B1

Author/
Year
Trial No./
Clinical Trial Phase
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Table 3. Cont.

Nucleotides

X

X

X
X

X

X

X

X
X
X

X

Royal Jelly

Muscadine Grape Extract

Coenzyme Q10

BHB

Fiber

EPA ± DHA

HMB

FA Fr Others

Glutamine

Carnitine

BCAA

Arginine

Essential amino acids

Cachexia

Whey protein isolate

HN

Lactoferrin

Yoshii 2014 [71]
Trial no. and phase NS

ProteinsAmino Acids

Quercetin

Vitamin B6
deficiency,
cachexia

Lycopene

Skin

Lipoic acid

Rauf 2011 [70]
Trial no. and phase N/A

Curcumin

NS

Antioxidants

Carbocysteine

PanC

Selenium

NS

Iron

Lung

Calcium

Malnutrition

Vitamin E

HN

Vitamin D

NS

Vitamin C

ProST

Vitamin B12

Weight loss

Wigmore 2000 [65]
Trial no. NS
Phase I/II
Zhuang 2021 [66]
NCT01882985
Phase II
Retrospective cohort observational
Barajas-Galindo 2020 [67]
Trial no. and phase NS
Singh 2017 [68]
Trial no. and phase NS
Case study
Ramalho 2017 [69]
Trial no. and phase N/A

Minerals

Vitamin B9

PanC

Vitamins

Vitamin B6

Conditions

Vitamin A

Cancer

Vitamin B1

Author/
Year
Trial No./
Clinical Trial Phase
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Table 3. Cont.

Conference Abstract
RCT
Haehling 2017 [72]
Trial no. and phase NS
Madeddu 2014 [73]
Trial no. and phase NS
Madeddu 2012 [74]
Trial no. NS
Phase III
Quasi-experimental trial
Garje 2019 [75]
NCT02535533
Phase I
Lugini 2013 [76]
Trial no. NS
Phase II
Mantovani 2012 [77]
Trial no. and phase NS
Serpe 2012 [78]
Trial no. and phase NS
Case Report
Ricottone 2017 [79]
Trial no. and phase N/A

NS

Cachexia

Renal

NS

NS

NS

Mixed

Cachexia

Mixed

Cachexia

HN

Anemia

X
X

X

X

X

X

X

X

X

X
X
X

X

Nucleotides

Royal Jelly

Muscadine Grape Extract

Coenzyme Q10

BHB

Fiber

EPA ± DHA

HMB

FA Fr Others

Glutamine

Carnitine

BCAA

Arginine

Essential amino acids

Whey protein isolate

Lactoferrin

Quercetin

Lycopene

Lipoic acid

ProteinsAmino Acids

X

Cachexia

Mixed

Curcumin

Antioxidants

Carbocysteine

Selenium

Iron

Calcium

Vitamin E

Vitamin D

Vitamin C

Vitamin B12

Cachexia

Minerals

Vitamin B9

Mixed

Vitamins

Vitamin B6

Conditions

Vitamin A

Cancer

Vitamin B1

Author/
Year
Trial No./
Clinical Trial Phase
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Clinical Trial Registration
RCT
NCT00398333 [80]
Phase IV
Quasi-experimental trial
NCT05119010 [81]
Phase NS

Nucleotides

Royal Jelly

Muscadine Grape Extract

Coenzyme Q10

BHB

Fiber

EPA ± DHA

HMB

FA Fr Others

Glutamine

Carnitine

BCAA

Arginine

Essential amino acids

Whey protein isolate

Lactoferrin

ProteinsAmino Acids

Quercetin

Lycopene

Lipoic acid

Curcumin

Antioxidants

Carbocysteine

Selenium

Iron

Calcium

Vitamin E

Vitamin D

NS

Vitamin C

Renal

Vitamin B12

NS

Minerals

Vitamin B9

COL

Vitamins

Vitamin B6

Conditions

Vitamin A

Cancer

Vitamin B1

Author/
Year
Trial No./
Clinical Trial Phase

X

X

NS: not specified; BCAA: branched chain amino acids; HMB: β-hydroxyl β-methyl butyrate; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; BHB: β-hydroxybutyrate;
HN: head and neck; FA: fatty acids; Fr: Fiber; COL: Colorectal; GYN: Gynecological; GI: Gastrointestinal; PanC: Pancreatic; ProST: Prostate.
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Vitamin D was administered in one RCT [40] and three quasi-experimental trials [59,62,64].
Vitamin D was the sole dietary supplement investigated and was provided in the form of
cholecalciferol to participants with vitamin D insufficiency, at a dose of 2000 IU daily in the
RCT [40] and 50,000 IU weekly in one of the quasi-experimental trials [59]. In the remaining
two quasi-experimental trials, Vitamin D was administered concomitantly with calcium,
either in the form of 2000 units ergocalciferol (commercially available liquid vitamin D
analogue) daily along with 500 mg calcium daily among participants with insufficient
vitamin D [64], or in the form of 0.5 µg 1α-OH vitamin D3 (1α-OHD3 ) daily along with 1 g
calcium carbonate daily [62].
In an observational study, iron was administered in the form of ferrous sulphate
200 mg twice daily at the initiation of chemotherapy as per clinic protocol, along with oral
vitamin B9 and vitamin B12 injection [68]. In a case report, iron was administered in the
form of 30 mg sucrosomial iron daily as a supportive intervention to radiation therapy in
a patient with sideropenic anemia [79]. Selenium was investigated in only one study (a
quasi-experimental trial) and was given in the form of seleno-L-methionine in doses of
2500, 3000, or 4000 µg twice daily for 14 days followed by once daily, in combination with
axitinib [75].
In terms of antioxidants other than vitamins and minerals, carbocysteine and lipoic
acid were administered concomitantly in three RCTs [42,44,74] and one quasi-experimental
trial [54]. A combination of carbocysteine and lipoic acid was administered in two RCTs
(that likely shared overlapping participants) as part of an antioxidant treatment (dosage
specified as 2.7 g carbocysteine daily and 600 mg lipoic acid daily in one of the RCTs) along
with dietary supplement carnitine [42,74]. In the remaining RCT and quasi-experimental
trial, carbocysteine (2.7 g daily) and lipoic acid (300 mg daily) were administered in
combination with quercetin, as well as EPA and the antioxidant vitamins A, C, E [44,54],
and either with or without additional carnitine in the RCT [44].
Curcumin was investigated as the sole dietary supplement in a quasi-experimental
trial in doses of 2 g daily (equivalent to 400 mg daily of active curcuminoids extract) [77].
In an RCT, curcumin was administered as part of a combined treatment including other
dietary supplements (carnitine and lactoferrin) at a dose of 4 g daily [73]. Lycopene was
investigated in only one study (quasi-experimental trial), where it was given at a dose of
30 mg daily in people receiving concomitant docetaxel therapy [66].
3.4.2. Proteins and Amino Acids
Protein supplements were investigated in three RCTs. Types of protein supplements
included in studies were whey protein isolate (n = 1) [38] and lactoferrin (n = 2) [43,73].
Whey protein isolate was administered in the form of two sachets of cysteine-rich lipid- and
lactose-free cow milk whey protein (Prother® ) consisting of 20 g protein [38]. Lactoferrin
was administered as two tablets daily (equivalent to 200 mg daily), along with recombinant
human erythropoietin, to people with anemia [43]. In another RCT, the same dose of
lactoferrin (200 mg daily) was administered along with carnitine and curcumin, as part of a
combined treatment, in people with cancer-related anemia and cachexia [73].
For amino acids, carnitine, an amino acid derivative, was the most investigated
and was included in seven studies, including five RCTs [41,42,44,73,74] and two quasiexperimental trials [53,56]. It was the sole dietary supplement investigated in two studies [41,53] and part of a combined treatment with other dietary supplements (EPA, branched
chain amino acids, coenzyme Q10, lipoic acid, carbocysteine, curcumin, lactoferrin, quercetin,
and/or vitamins A, C, and E) in five studies [42,44,56,73,74]. Carnitine was given as L-carnitine
and in doses of 50 mg, 2 g, 4 g, or 6 g daily in included studies.
Arginine was the second most commonly investigated amino acid. Arginine was the
main dietary supplement investigated in an RCT where it was administered in the form
of a specially formulated enteral formula and replaced 41% of casein [36], as well as in an
observational study where it was given in the form of an immunonutrition enteral formula
(Impact® ) containing 12.5 g/L L-arginine, dietary nucleotides, EPA, and docosahexaenoic
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acid (DHA) [67]. Arginine was investigated as part of a combined treatment with glutamine
(amino acid) and β-hydroxyl β-methyl butyrate (HMB) (amino acid metabolite) in three
studies (two RCTs [35,45] and one quasi-experimental trial [57]), which were also the only
studies where glutamine or HMB were included. Daily doses were in the following ranges:
14–28 g arginine, 14–28 g glutamine, and 2.4–6 g HMB daily [35,45,57].
Branched chain amino acids (BCAA) were investigated in a quasi-experimental trial,
where they were administered in the form of an enriched ONS (Inner Power® ), which
consists of 2500 mg BCAA per pack, along with coenzyme Q10 and carnitine, with one pack
given daily [56]. Two studies, an RCT [72] and a quasi-experimental trial [76], included
all the essential amino acids. In the RCT, a 4 g essential amino acid powder was the sole
intervention and was given thrice daily (equivalent to 12 g amino acids daily) [72]. In the
quasi-experimental trial, essential amino acids were given in the form of two sachets of
Aminotrific® supplement, which also consisted of vitamins B1 and B6 [76].
3.4.3. Fatty Acids
Omega-3 fatty acids, EPA and DHA, were the most commonly investigated dietary
supplement overall (n = 18), and were studied in nine RCTs [37,39,44,47–51,80], six quasiexperimental trials [54,55,58,63,65,78], one observational study [67], and two case studies [69,71]. Omega-3 fatty acids were administered in the form of free EPA acids [65],
purified EPA + DHA capsules [69], krill oil capsules [78], fish oil capsules [37,39,47,55],
fish oil liquid [55], marine phospholipids [63], or in fortified ONS [44,48–51,54,58,67,71,80].
Marine phospholipids and krill oil consisted of omega-3 fatty acids that were bound to
phospholipids, which were suggested by study authors to have a different uptake and
metabolism from those bound to triacylglycerols (such as those in fish oil) [63,78]. With
the exception of one study where omega-3 was administered enterally [71], omega-3 was
given orally for all. Reported doses ranged from 1.1 g to 6 g EPA daily and 0.2 to 2.7 g
DHA daily [37,39,44,47,49–51,54,55,58,65,69,71]. Omega-3 fatty acids were the only dietary
supplement included in 13 studies [37,47–51,55,58,63,65,71,78,80], while additional dietary
supplements (e.g., carnitine, arginine, dietary nucleotides, fiber, quercetin, lipoic acid,
carbocysteine, and vitamins A, C, and E) were included in five studies [39,44,54,67,69].
Although DHA was not explicitly mentioned in some studies, it was present along with
EPA by virtue of the forms in which EPA was administered [44,48,50,51,55,71,80].
3.4.4. Fiber
Fiber was only included in one case study where omega-3 fatty acids were the main
dietary supplement of interest [69]. The participant consumed one serving of fortified ONS
(Forticare Nutricia) daily, which contains both EPA and fiber and provides 2.6 g fiber daily.
3.4.5. Others
Other dietary supplements that were investigated were β-hydroxybutyrate (BHB) [81],
coenzyme Q10 [56], muscadine grape extract [52], dietary nucleotides [67], and royal
jelly [34]. The supplement BHB was included in a quasi-experimental trial that has not
started recruitment yet and will be administered in the form of liquid ketone supplement,
two tablespoons three times daily (providing 1 g/kg body weight daily of BHB) [81].
Coenzyme Q10 was administered in a quasi-experimental trial in the form of one pack of
enriched ONS (Inner Power® which contains BCAA, carnitine, and 30 mg coenzyme Q10
per pack) daily [56]. Muscadine grape extract was investigated in a quasi-experimental
trial in the form of capsules that were taken twice daily (each capsule containing ~160 mg
phenolics) in five dose levels of 320 to 1600 mg total phenolics [52]. Royal jelly was
administered in the form of 800 mg capsules three times daily (equivalent to 2400 mg daily),
as per figures published in the erratum [82].
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3.5. Concomitant Interventions
Of the 48 studies, single dietary supplements were administered on their own, without concomitant interventions, in 19 studies (e.g., omega-3 only) [34,38,40,41,47,52,55,59,62–66,70,72,75,77–79].
The remaining 29 studies had single dietary supplements administered with other dietary
supplements (e.g., omega-3 and arginine), ONS, counseling, exercise, and/or non-cancer
specific drugs. Non-cancer specific drugs prescribed concomitantly in those studies were
celecoxib [37,42,50,54,73,74], medroxyprogesterone acetate or megestrol acetate [42,44,54,74],
thalidomide [44], or recombinant human erythropoietin [43].
In studies with concomitant interventions, dietary supplements were administered
with ONS in 12 studies and were used to fortify/enrich ONS in some studies. Oral nutritional supplements were the only other intervention in three studies [36,49,51], while
different types of dietary supplements were used as a combination (i.e., omega-3 and
arginine) in addition to ONS in two studies [67,71]. In the remaining studies with ONS,
dietary supplements were also used in conjunction with nutritional counseling [58,80],
prescribed diet [48], drug [37], or a combination of drug, nutritional counseling, and exercise (home-based aerobic and resistance training) [50], or were part of a combination
of dietary supplements and drugs [44,54]. In the 17 studies with concomitant interventions but without ONS, dietary supplements were delivered concurrently with drugs [43]
or nutritional counseling [38], or as part of a combination with other dietary supplements [35,39,45,46,60,61,68,76] that were accompanied by drugs [42,73,74], or in-person
structured nutrition, exercise, and symptom advice via the Macmillan Durham Cachexia
Pack [57], or in-person individualized nutritional and exercise counseling along with
prescription of individualized home-based resistance training [56].
3.6. Malnutrition-Related Conditions
The malnutrition-related conditions investigated in the included studies included cachexia
(n = 14) [37,44,50,51,56,57,63,70–74,77,78], weight loss (n = 10) [35,41,42,45,47,48,54–56,65],
malnutrition (n = 6) [36,38,39,48,58,67], vitamin D deficiency (n = 3) [40,59,64], anorexia
(n = 2) [37,47] vitamin B6 deficiency (n = 1) [70], muscle depletion (n = 1) [56], and cancerrelated anemia (n = 1) [43]. The specific malnutrition-related conditions were not specified
in other studies (n = 15) [34,46,49,52,53,60–62,66,68,69,75,76,80,81]. Cachexia was most
commonly investigated, and where reported, definitions were variable and included the
following: >2% weight loss in patients with BMI <20 kg/m2 [56], >5% weight loss according
to ideal or pre-illness body weight in the past three months [44], >5% weight loss in the
past six months [56,73], >5% weight loss since first diagnosis [63], >10% weight loss [37], or
the presence of muscle depletion [56]. No study investigated frailty or sarcopenia (both in
accordance with published definitions), and only one study included patients with muscle
depletion [56], defined by lumbar skeletal muscle index cut-offs [83].
3.7. Cancer Types
Dietary supplements that were investigated in the included studies varied across
different cancer types, as illustrated in Figure 2. Omega-3 fatty acids (EPA and/or DHA)
showed the most consistency, where they were among the most ubiquitous dietary supplements for mixed or unspecified cancer types (n = 7) [39,44,47,50,54,63,78], as well as for the
individual cancer types—lung (n = 3) [37,48,55], head and neck (n = 2) [67,71], pancreatic
(n = 3) [51,65,69], and colorectal cancers (n = 2) [58,80].
In terms of individual cancer types, and beyond omega-3, the predominant dietary
supplements investigated were vitamin B9 in lung cancer (n = 4) [46,60,61,68], arginine
in head and neck cancer (n = 2) [36,67], and vitamin D plus calcium in prostate cancer
(n = 2) [62,64]. All remaining dietary supplements investigated in individual cancer types
were present only in one study in each of the cancer types. For mixed or unspecified cancer
types, carnitine (n = 5) [44,53,56,73,74] was most commonly prescribed after omega-3,
followed by vitamin E (n = 3) [39,44,54], carbocysteine (n = 3) [44,54,74], and lipoic acid
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(n = 3) [44,54,74]. The remaining dietary supplements investigated in mixed or unspecified
cancer types were only present in one or two studies each.

Figure 2. Types of dietary supplements included in studies, according to cancer type.

3.8. Proposed Effects, Mechanisms/Rationale, and Outcome Measures
As shown in Table 4, dietary supplements were hypothesized to improve malnutritionrelated conditions in a majority of the studies [35,37,38,41–45,47–51,54,57,59,63–65,71–74,76–79].
In some studies, the hypothesized main effects of dietary supplements were related to
benefits that were not directly relevant to malnutrition-related conditions. These were
improvements in survival [40], symptoms of cancer metastasis (e.g., pain) [64], antitumor
efficacy of chemotherapy [66], and treatment response [75]; counteracting adverse effects of
chemotherapy, (e.g., anti-folate effects of pemetrexed) [46,60,61,68], bone loss from complete
androgenic blockade use [62], muscle and joint pain from estrogen blockade use [59], and
inflammation; oxidative stress immune system dysfunction induced by tyrosine kinase
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inhibitors [34]; and counteracting adverse effects of other dietary supplements that are
concomitantly administered (such as compensating for the oxidative effect of omega-3
supplements) [39].
Table 4. Hypothesized effects of dietary supplements, mechanisms/rationale, and outcomes measures assessed.
Proposed Mechanisms or Rationale

Outcome Measures in Studies
Where the Dietary Supplement
Was Included

Reduces proinflammatory cytokines to
improve oxidative stress and CACS
symptoms, as part of a combination of
antioxidants, ONS, and drugs [44,54].

Weight; LBM; grip strength; REE;
leptin, proinflammatory cytokines,
antioxidant enzymes, and ROS
levels; appetite; fatigue; physical
activity level; performance status;
QoL; prognostic score.

Useful in muscle trophism, along with
Vitamin B6 and amino acids [76].

Nutritional status, clinical status,
QoL, adherence to chemotherapy.

Oral replacement therapy corrects Vitamin
B6 deficiency and its associated
neutropenia [70].
Useful in muscle trophism, along with
Vitamin B1 and amino acids [76].

Nutritional status; vitamin B6 and
neutrophil levels; clinical status;
QoL, regression of cervical
adenopathy; adherence to
chemotherapy.

Vitamin B9

Reduces adverse events from pemetrexed
therapy [46,60,61,68].

Reduces toxicity to pemetrexed (an
antifolate) when used with Vitamin B12
[46,60,61,68]. Vitamin B9 dosing, however,
needs to be optimal to prevent interference
with pemetrexed effectiveness [68].

Total plasma homocysteine levels,
QoL, relative dose intensity,
tumor response, survival, adverse
events (including neutropenia
grade and other toxicities).

Vitamin B12

Oral vitamin B12 is an alternative to
intramuscular vitamin B12 for purposes of
reducing pemetrexed-associated adverse
events, when used along with Vitamin B9
[60].

Oral administration of vitamin B12 is
capable of correcting vitamin B12
deficiency and is, thus, an alternative to
intramuscular injection [60].

Total plasma homocysteine levels,
tumor response, survival, adverse
events (including neutropenia
grade and other toxicities).

Vitamin C

Functions as an antioxidant agent to
improve CACS as part of an integrated
treatment [44,54].

Reduces proinflammatory cytokines to
improve oxidative stress and CACS
symptoms, as part of a combination of
antioxidants, ONS, and drugs [44,54].

Weight; LBM; grip strength; REE;
leptin, proinflammatory
cytokines, antioxidant enzymes
and ROS levels; appetite; fatigue;
performance status; physical
activity; QoL; prognostic score.

Vitamin D

Improves survival in metastatic colorectal
cancer [40].
Replacement therapy improves muscle
strength and pain associated with prostate
cancer bone metastasis [64].
1α-OHD3 along with calcium
supplementation prevents bone mass loss
in men with prostate cancer treated with
complete androgenic blockade [62].
Improves symptom burden in women
with estrogen receptive–positive
metastatic breast cancer [59].

Exerts anti-cancer effects when converted
to calcitriol in the body, by regulating
cancer-related genes [40].
Inhibits growth of prostate cancer cells
[64].
1α-OH vitamin D3, along with calcium,
prevents bone mass loss [62].
Supplementation improves vitamin D
insufficiency to reduce muscle and joint
pain that stem from estrogen blockade use
and low serum 25-hydroxyvitamin D
(25[OH]D) levels [59].

Anthropometry, bone mineral
density, muscle strength, grip
strength, 25(OH)D levels, calcium
phosphatase and alkaline
phosphatase levels, prostate
specific antigen levels, CRP levels,
proinflammatory cytokines levels,
symptom burden, pain, QoL,
survival.

Functions as an antioxidant agent to
improve CACS as part of an integrated
treatment [44,54].
Minimizes side effects of omega-3
supplementation [39].

Reduces proinflammatory cytokines to
improve oxidative stress and CACS
symptoms, as part of a combination of
antioxidants, ONS, and drugs [44,54].
Compensates for the oxidative effect of
omega-3 [39].

Weight; LBM; grip strength; REE;
leptin, albumin, transferrin,
proinflammatory cytokines, T-cell
subsets, antioxidant enzymes, and
ROS levels; appetite; fatigue;
performance status; physical
activity; QoL; prognostic score;
survival.

Dietary
Supplement

Hypothesized Effects

Vitamins, minerals, and other antioxidants

Vitamin A

Vitamin B1

Vitamin B6

Vitamin E

Functions as an antioxidant agent to
improve CACS as part of an integrated
treatment [44,54].
Contributes to prevention of anorexia and
cachexia along with Vitamin B6 and amino
acids during chemotherapy [76].
Oral replacement therapy corrects
neutropenia that stems from Vitamin B6
deficiency [70].
Contributes to prevention of anorexia and
cachexia along with Vitamin B1 and amino
acids during chemotherapy [76].

Nutrients 2022, 14, 2642

19 of 29

Table 4. Cont.
Dietary
Supplement

Hypothesized Effects

Calcium

Prevents bone mass loss in men treated
with complete androgenic blockade, along
with 1α-OHD3 [62].

Iron

Improves sideropenic anemia when
administered in the form of sucrosomial
iron, as a supportive therapy alongside
radiation therapy [79].

Selenium

Improves axitinib therapy response when
administered in the form of
seleno-L-methionine [75].

Carbocysteine

Functions as an antioxidant agent to
improve cancer cachexia symptoms as part
of an integrated treatment [42,44,54,74].

Curcumin

Improves nutritional and
immunometabolic alterations of cachexia
and cancer-related anemia as part of a
combined treatment also consisting of
L-carnitine, lactoferrin and celecoxib [73].
Exerts antioxidant and anti-inflammatory
effects in advanced cancer cachexia [77].

Lipoic acid

Functions as an antioxidant agent to
improve cancer cachexia symptoms as part
of an integrated treatment [42,44,54,74].

Lycopene

Concomitant administration with
docetaxel is an effective treatment for
prostate cancer [66].

Quercetin

Functions as an antioxidant agent to
improve CACS as part of an integrated
treatment [44,54].

Proposed Mechanisms or Rationale
Calcium, along with 1α-OH vitamin D3,
prevents bone mass loss, which people
with advanced prostate cancer receiving
complete androgenic blockade are more
susceptible to [62].
As radiation therapy can lead to
side-effects such as mucositis and
dysphagia resulting in malnutrition and
subsequent onset of sideropenic anemia,
sucrosomial iron improves sideropenic
anemia when given concomitantly with
radiation therapy [79].
Seleno-L-methionine stabilizes tumor
vasculature and reduces risks of
angiogenesis, tumor metastasis and
treatment resistance when given in
combination with chemotherapeutic and
vascular endothelial growth
factor–targeted agents [75].
Reduces proinflammatory cytokines to
improve oxidative stress and CACS
symptoms, as part of a combination of
antioxidants, ONS, and drugs [44,54].
Important precursor of cell-reduced
glutathione and counteracts oxidative
stress [42].
Possesses anti-inflammatory and
antioxidant effects to mitigate
inflammation and oxidative stress in
cachexia [73,77].
Reduces proinflammatory cytokines to
improve oxidative stress and CACS
symptoms as part of a combination of
antioxidants, ONS, and drugs [44,54].
Important precursor of cell-reduced
glutathione and counteracts oxidative
stress [42].
Possesses antioxidant properties and has
chemo preventive effects in prostate
cancer; inhibits antiapoptotic protein, and
improves antitumor efficacy of docetaxel
[66].

Outcome Measures in Studies
Where the Dietary Supplement
Was Included
Bone mineral density; muscle
strength; 25(OH)D, calcium
phosphatase, alkaline
phosphatase, and prostate specific
anti-gen levels; pain.
Weight; hemoglobin, mean
corpuscular, mean corpuscular
hemoglobin, and total plasma
homocysteine levels; mucositis;
tumor response; toxicity.

Response, survival, adverse
events; toxicity.

Weight; LBM; grip strength; REE;
leptin, CRP, proinflammatory
cytokines, ROS, and antioxidant
enzyme levels; appetite; fatigue;
performance status; physical
activity level; QoL; prognostic
score; adverse events.
LBM; serum iron, ferritin,
hepcidin, erythropoietin, CRP,
proinflammatory cytokines, ROS,
antioxidant enzyme, and total
blood antioxidant status levels;
appetite; fatigue; anemia.
Weight; LBM; grip strength; REE;
leptin, CRP, proinflammatory
cytokines, ROS, and antioxidant
enzyme levels; appetite; fatigue;
performance status; physical
activity level; QoL; prognostic
score; adverse events.
Prostate specific antigen response,
survival, adverse events.

Reduces proinflammatory cytokines to
improve oxidative stress and CACS
symptoms when used in a combination of
antioxidants, ONS, and drugs [44,54].

Weight; LBM; grip strength, REE;
leptin, proinflammatory
cytokines, antioxidant enzymes,
and ROS levels; appetite; fatigue;
performance status; physical
activity level; QoL; prognostic
score.

Key in host defense against infection and
excessive inflammation [43].
As patients with cancer anemia may have
low or normal serum iron levels, yet
increased ferritin levels and rich bone
marrow iron reserves, it is suggested that
cancer anemia is associated with flaws in
iron use rather than iron shortage [43].
Lactoferrin, which is involved in iron
transport mechanisms, can thus treat this
form of iron-related anemia [43,73].

LBM; hematopoietic response;
erythrocyte sedimentation rate;
hemoglobin, iron, ferritin,
hepcidin, erythropoietin, CRP,
proinflammatory cytokine, ROS,
and antioxidant enzyme levels;
appetite; fatigue; anemia; adverse
events.

Proteins and amino acids

Lactoferrin

Improves nutritional and
immunometabolic alterations of cachexia
and cancer-related anemia as part of a
combined treatment with L-carnitine,
curcumin and celecoxib [73].
An alternative to intravenous iron
supplementation when combined with
recombinant human erythropoietin, in the
treatment of anemia in advanced cancer
during chemotherapy [43].
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Table 4. Cont.
Hypothesized Effects

Proposed Mechanisms or Rationale

Outcome Measures in Studies
Where the Dietary Supplement
Was Included

Whey protein
isolate

Improves nutritional status of
malnourished advanced cancer patients
receiving chemotherapy [38].

Possesses immune-enhancing factors and
contains cysteine (a limiting amino acid in
the glutathione production), where
glutathione protects cells from free
radicals and carcinogens.
Induces more muscle protein synthesis,
being more rapidly digested than other
protein sources [38].

Weight, phase angle, fat-free mass
index, grip strength, protein
calorie intake, QoL, chemotherapy
toxicity.

All essential
amino acids

Counter wasting processes associated
with cancer cachexia [72].
Prevents anorexia and cachexia in cancer
during chemotherapy, along with vitamins
B1 and B6 [76].

Useful in muscle trophism, along with
vitamins B1 and B6 [76].

Weight, body composition,
nutritional status, clinical status,
muscle strength, exercise capacity,
QoL, adherence to chemotherapy.

Conditionally essential amino acid that
acts as a substrate for nitric oxide
synthesis (which is potentially toxic to
cancer cells), improves immune function
[36,45,67], modulates protein turnover
[45], fights remnant cancer cells following
surgical removal of malignant tumors [36],
and improves wound healing [35,67].
Works in synergy with HMB to mitigate
muscle loss, and with both HMB and
glutamine to reduce muscle damage from
ROS and proinflammatory cytokines [57].

Weight; body composition; LBM;
grip strength; energy and protein
intake; liver function; renal
function; total protein,
prealbumin, albumin, globulin,
retinol-binding protein, total
cholesterol, and triglycerides
levels; fatigue; QoL; need for
parenteral nutrition during
hospital admission; duration of
tube feeding; length of hospital
stay; fistula incidence after
surgery; readmission rates;
treatment success; cancer
recurrence; metastases or second
primary tumors occurrence;
survival.

Not specified

Weight, BMI, LBM, nutritional
status, food intake, physical
function/muscle strength,
physical activity levels.

Dietary
Supplement

Arginine

Prevents cancer recurrence following
surgical removal of malignant tumors,
especially when administered
perioperatively [36].
Improves postoperative recovery as part
of an immunonutrition enteral formula in
head and neck cancer [67].
Prevents LBM loss and reverses cancer
cachexia, as part of a mixture with HMB
and glutamine [35,45].
Delays cachexia onset in advanced lung
cancer [57].

Branched chain
amino acids
(BCAA)

Improves physical function in elderly
patients with advanced lung or pancreatic
cancer as part of a multimodal
intervention with coQ10 and L-carnitine
[56].

Carnitine

Improves cancer cachexia in pancreatic
cancer [41], and improves fatigue and ROS
levels in advanced cancer [53].
As part of a combined treatment, improves
cancer cachexia symptoms [42,44,73,74],
cancer-related anemia [73], and physical
function in elderly patients with advanced
lung or pancreatic cancer [56].

Modulates inflammatory response
mechanisms associated with cancer
cachexia [41]. Deficiency contributes to
cancer cachexia and tumor-associated
fatigue [41].
Key in β-oxidation and energy and amino
acid metabolism [42,44,53,73].

Glutamine

As part of a mixture with arginine and
HMB, prevents LBM loss and reverses
cancer cachexia [35,45] or delays cachexia
onset in advanced lung cancer [57].

Regulates muscle protein synthesis or
turnover [35,57] and exerts immune
stimulatory effects [45]. Works with both
HMB and arginine to reduce muscle
damage from ROS and pro-inflammatory
cytokines [57].

Weight; BMI; body composition;
LBM; skeletal muscle analysis;
grip strength; food intake;
nutritional status; nutrition
impact symptoms; REE;
L-carnitine, iron, ferritin, hepcidin,
erythropoietin, hemoglobin; CRP,
proinflammatory cytokines, ROS,
and antioxidant enzyme levels;
appetite; fatigue; performance
status; physical function; physical
activity level; QoL; global health
status; prognostic score; survival;
anemia; adverse events/toxicity.
Weight; body composition; LBM;
grip strength; calorie and protein
intake; liver function; renal
function; total protein, albumin,
globulin, prealbumin, triglyceries
and total cholesterol levels;
fatigue; QoL; treatment success.
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Table 4. Cont.
Dietary
Supplement

HMB

Hypothesized Effects

Proposed Mechanisms or Rationale

As part of a mixture with arginine and
glutamine, prevents LBM loss and
reverses cancer cachexia [35,45] or delays
cachexia onset in advanced lung cancer
[57].

Modulates protein turnover [45,57] and
works in synergy with arginine to mitigate
muscle loss [57].
Improves nitrogen balance, inhibits
proteolysis-inducing factor [35], and
works with arginine and glutamine to
reduce muscle damage from ROS and
pro-inflammatory cytokines [57].

Outcome Measures in Studies
Where the Dietary Supplement
Was Included
Weight; body composition; LBM;
grip strength; calorie and protein
intake; liver function; renal
function; total protein, albumin,
globulin and prealbumin levels;
triglyceries and total cholesterol
levels; fatigue; QoL; treatment
success.

Fatty Acids

EPA ±
docosahexaenoic
acid (DHA)

Modifies membrane composition of
neutrophils to reduce inflammation and
wasting in advanced cancer [47], improves
T-cell subsets and cytokine production
when used along with vitamin E [39], and
improves SIMS symptoms [37]. Omega-3–
or EPA–containing ONS improves
nutritional, clinical and inflammatory
parameters, and health-related QoL in
advanced lung cancer [48]; improves
prognosis in advanced gastrointestinal
cancer [49] and hypopharyngeal cancer
among patients on induction
chemotherapy [71]; and improves
cachexia during gemcitabine therapy [51].
Improves postoperative recovery in head
and neck cancer, as part of an
immunonutrition formula [67].
Omega-3–containing ONS as part of a
multimodal intervention improves clinical
outcomes in cancer [69] and attenuates
cachexia in incurable lung or pancreatic
cancer [50] or advanced cancer with CACS
[44,54].
Marine phospholipids (with >50%
phospholipid-bound fatty acids as EPA
and DHA) aid in cancer cachexia
management [63].
Omega-3 fatty acids (EPA and DHA) in
krill oil improve lipid profile disorder and
inflammatory processes associated with
cachexia [78]. A more purified EPA +
DHA supplement is more reliable than
fish oil supplements [69].
EPA is a biologically active component of
fish oil responsible for anticachectic
activity [65].

Immunomodulatory [49,63,65,71], with
EPA in particular having
anti-inflammatory, anticachectic,
antitumoral, anti-genotoxic, and
antioxidant properties [48,49,63,65,71].
EPA partially substitutes arachidonic acid,
thereby reducing production of
arachidonic acid–derived mediators to
exert an anti-inflammatory effect [37,63].
Omega-3 augments defense against tumor
cells and tumor cell susceptibility by
altering cell membrane composition and
directly reducing tumor cell proliferation
[39]. By inhibiting proinflammatory
cytokines production [48,49,63,65,71],
omega-3 improves cancer cachexia
[44,51,63,65] and reduces proinflammatory
mediators to lower infections [67].
As fatty acids bound to
phospholipids-bound are more readily
incorporated into plasma phospholipids
compared to those bound to
triacylglycerols, marine phospholipids can
be more effective in a lower dose than fish
oil in cancer patients [63].
A purified EPA/DHA supplement offers
better outcomes due to possible
interactions between platinum-based
chemotherapy and fatty acids present in
fish oils [69].

Weight; height; BMI; fat mass;
subcutaneous and visceral
adipose tissue; LBM; muscle mass;
skeletal muscle; phase angle;
intracellular water; extracellular
water; total body water; grip
strength; REE; nutritional status;
nutritional, caloric intake and fat
intake; complete blood cell count;
white blood cell count; leukocytes,
thrombocytes, leptin,
retinol-binding protein, albumin,
pre-albumin, transferrin, total
protein, hemoglobin, glucose,
sodium, potassium, ionic calcium,
creatinine, urea, total and direct
bilirubin, aspartate amino
transaminase, alanine amino
transaminase, lactate
dehydrogenase, gamma-glutamyl
transferase; gamma glutamil
transpeptidase, alkaline
phosphatase, creatinine, CRP,
ROS, antioxidant enzyme,
cytokine, T-cell subsets,
carcino-embryonic antigen,
carbohydrate antigen 19.9/125,
lyso-phosphatidylcholine. total
cholesterol, high-density
lipoprotein, low-density
lipoprotein, very low–density
lipoprotein, and triglycerides
levels; plasma phospholipid, red
blood cell, mononuclear
lymphocytes, and neutrophil fatty
acid composition; appetite;
nausea; vomiting; diarrhea;
energy level; physical and overall
well-being; fatigue; physical
activity level, physical function;
performance status; QoL;
health-related QoL; disease
progression; prognostic score;
survival; toxicity; adverse events;
safety; therapy response;
chemotherapy dose reductions;
need for parenteral nutrition
during admission; duration of
tube feeding; fistula incidence
after surgery; mortality; hospital
length of stay; hospitalizations;
recurrence; readmissions;
adherence to intervention.
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Table 4. Cont.
Proposed Mechanisms or Rationale

Outcome Measures in Studies
Where the Dietary Supplement
Was Included

Not reported

Not reported

Weight, muscle mass, fat-free
mass, fat mass; hemoglobin,
glucose, CRP, albumin, AAT, GGT,
carcinoembryonic antigen, and
carbohydrate antigen 19.9/125
levels.

Intake is safe when used while receiving
immunotherapy for cancer [81].

Not reported

CoQ10

Improves physical function in elderly
patients with advanced lung or pancreatic
cancer as part of a multimodal
intervention [56].

Not reported

Muscadine grape
extract (MGE)

Improves cancer outcomes by reducing
symptom burden and is tolerated and safe
for use in patients with metastatic solid
tumors who have failed standard
therapies [52].

Muscadine grape contains a high
concentration of anthocyanin, ellagic acid,
gallic acid, and flavonols and has
antioxidant properties. It inhibits tumor
cell growth and induces apoptosis, while
also reducing systemic inflammation [52].

Dietary
nucleotides

Improves postoperative recovery in head
and neck cancer as part of an
immunonutrition enteral formula [67].

Modulates inflammatory and immune
response [67].

Royal jelly

Protects from toxicities induced by
tyrosine kinase inhibitors in renal cancer
[34].

Possesses anti-inflammatory and
antioxidative effects, influences immune
system, and protects from adverse events
such as inflammation, oxidative stress and
immune system dysfunction induced by
anticancer agents [34].

Dietary
Supplement

Hypothesized Effects

Fiber

Fiber

Others
βhydroxybutyrate
(BHB)

Weight; sarcopenia; albuminemia;
prealbuminemia; CRP level; QoL;
response rate; survival; safety.
Weight, BMI, skeletal muscle
analysis, grip strength, food
intake, nutritional status,
nutrition impact symptoms,
physical function, physical
activity levels.
CRP, hepatocyte growth factor,
IL-6, IL-6 receptor, IL-8,
platelet-derived growth factor,
TNF-α, vascular endothelial
growth factor and phenolic levels;
fatigue, QoL, response rate; safety;
survival; adherence to
intervention.
Weight, energy and protein intake,
albumin levels, retinol binding
protein levels, duration of tube
feeding, need for parenteral
nutrition during admission,
fistula incidence after surgery,
length of hospital stay,
readmission rates, mortality.
Tumor necrosis and transforming
growth factor levels, adverse
events due to tyrosine kinase
inhibitors, sustained period of
initial tyrosine kinase inhibitors.

1α-OH vitamin D3: 1α-OHD3; CACS: cancer-related anorexia/cachexia syndrome; ONS: oral nutritional supplements; LBM: lean body mass; REE: resting energy expenditure; ROS: reactive oxygen species; QoL: quality
of life; CRP: C-reactive protein; HMB: β-hydroxyl β-methyl butyrate; BMI: body mass index; SIMS: systemic
immune-metabolic syndrome; COX: cyclooxygenases; AAT: alanine aminotransferase; GGT: gamma-glutamyl
transferase; IL: interleukin; TNF: tumor necrosis factor.

The intended attributes of dietary supplements included antioxidant [39,42,44,49,52,54,63,66,71,74,77],
anti-inflammatory [34,37,41,43,44,48,49,51,52,63,65,67,71,77], anti-cancer [36,40,48,64–66],
and immunomodulatory [34,36,38,45,49,63,65,67,71] properties; ability to reduce infections [43,67], facilitate wound healing [35,67], improve physical function [56], improve
muscle strength [64], mitigate muscle loss and reduce muscle damage [35,45,57], improve
muscle trophism [38,76], and regulate protein synthesis or turnover [35,57]; and having a
role in energy and amino acid metabolism [42,44,53,73].
3.9. Tools Used in Outcome Measurements
The tools that were used to assess each of the different outcome measures, where
specified, are presented in Table 5.
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Table 5. Outcome measures and corresponding tools used in included studies.
Outcome Measures

Tools Used
Two-day or three-day food diary, 24-h diet recall; 10-point verbal scale
assessment of nutritional intake [38,50,56,58]

Nutritional intake
Nutritional status

MNA; PG-SGA [50,56]

Body composition (including fat-free mass, LBM, muscle mass)

Midarm muscle circumference measurement; skin-fold measurement
techniques; body plethysmography; air displacement plethysmograph;
BIA; BIVA; CT; DEXA [35,37,38,41,42,44,45,48–50,53–58,63,65,72]

Phase angle

BIVA; BIA [38,48]

Grip strength

Handgrip Dynamometer [38,42,44,50,53,54,56,57]

Muscle strength/physical performance/exercise capacity

Five times sit-to-stand or chair rise test; 5-m gait speed; 10-m gait speed;
stair-climbing power; 6-min walk distance [50,56,64,72]

Resting energy expenditure

Indirect calorimetry [42,44,54]

Fatigue

MFSI-SF; Brief Fatigue Inventory questionnaire; Schwarz Fatigue Index;
numerical rating scale 0–10; Fatigue Severity Scale; PROMIS-fatigue
[35,37,41,42,44,50,52–54]

Appetite

VAS; numerical rating scale 0–10 [37,42,44,54,63]

Nausea

Numerical rating scale 0–10 [37]

Performance status

ECOG PS scale; Karnofsky performance status/score [37,39,44,51,54]

Physical activity level

Electronic wearable device (armband/pedometer/accelerometer/logger)
[44,50,56]

QoL

EORTC QLQ-C30; EORTC-QLQ-C30 questionnaire with pancreatic
cancer–specific module PAN 26; Italian version of EORTC QLQ-C30;
QLQ-LC13, EQ-5D; QoL-ACD; FAACT; FACT-L; FACT-G; Functional
Assessment Health Survey; Functional Assessment of Cancer
Therapy–General as well as –Bone Pain, –Breast and –Endocrine
Symptoms subscales; Spitzer Quality of Life Index; Short Form-36 Health
Survey; Quality of Life–Oxidative Stress Questionnaire; disease and
treatment assessment form [35,38,41,42,44–46,48,52,54,57–59,63,80,81]

Symptom burden

Brief Pain Inventory; Piper Fatigue Scale; Hospital Anxiety and
Depression Scale; and Pittsburg Sleep Quality Index [59]

Pain

Modified McGill–Dartmouth Pain Questionnaire [64]

Prognosis

GPS [44,74]

Regression of cervical adenopathy

Clinical examination; positron emission tomography (PET); CT [70]

Treatment response

CT, magnetic imaging resonance imaging, or X-ray [52,55]

Tumor response

RECIST [46,51,60,61,68,81]

Toxicity or adverse events

National Cancer Institute Common Toxicity Criteria for Adverse Events;
National Cancer Institute Common Toxicology Criteria; National Cancer
Institute Common Terminology Criteria for Adverse Events version 3.0 or
4.0; National Cancer Institute’s Common Toxicity Criteria version 2.0
[38,42,43,46,48,50,51,53,58,60,61,66,68]
MNA: Mini Nutritional Assessment; aPG-SGA: abridged Patient Generated Subjective Global Assessment;
LBM: Lean Body mass; BIA: Bioelectrical Impedance Analysis; BIVA: bioelectrical impedance vector analysis;
CT: computed tomography; DEXA: Dual-Energy X-ray Absorptiometry; MFSI-SF: Multidimensional Fatigue
Symptom Inventory—Short Form; PROMIS: Patient reported Outcomes Measurement and Information System;
VAS: Visual Analog Scale; ECOG PS: Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30:
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30; EQ-5D: EuroQoL
5 Dimension; QoL: Quality of Life; QoL-ACD: Questionnaire for Cancer Patients Treated with Anticancer Drugs;
FAACT: Functional Assessment of Anorexia Cachexia Therapy questionnaire; FACT-L: Functional Assessment of
Cancer Therapy for Lung Cancer; FACT-G: Functional Assessment of Cancer Therapy-General; GPS: Glasgow
Prognostic Score; RECIST: Response Evaluation Criteria in Solid Tumors.

4. Discussion
This scoping review summarized the types of dietary supplements used in studies
involving metastatic cancer patients with malnutrition-related conditions. Thirty-one supplements were identified, which varied across different cancer types. Dietary supplements
were investigated as part of combined treatments in most of the studies, where they could
be administered as single (i.e., omega-3) or multiple types (i.e., omega-3 + arginine), or
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along with ONS, other dietary supplements, counseling, exercise, and/or drugs. Omega-3
and L-carnitine were the top two most predominantly investigated supplements—omega-3
for its anti-inflammatory [37,44,49,51,63,71], antioxidant [49,63,71], and immunomodulatory [49,63,65,71] properties, and carnitine for its suggested benefits in the modulation of
inflammatory response mechanisms that have been associated with cancer cachexia [41]
and role in metabolism [42,44,53,73]. To combat oxidative stress and manage the complexity
of cancer-related malnutrition, multimodal treatments were considered necessary to reduce
proinflammatory cytokines [44,54]. Metastasis itself is a complex challenge that necessitates
multimodal therapeutic agents for effective inhibition [2] and managing its associated
syndromes. While multimodal interventions may confer benefits over single interventions,
it is challenging to identify the individual contribution of dietary supplements to any
beneficial effects seen. Hence, it might be worthwhile investigating this with multi-arm
RCTs, including both single and combined interventions which are compared to controls in
future studies.
Overall, the included studies consistently reported positive effects for multimodal
treatments as well as omega-3 supplements. Evidence for vitamins, minerals, and amino
acids was less consistent. While antioxidants and other dietary supplements were reported
by studies to exert positive effects, the number of studies that they have been included
in were scant. As the present scoping review was, however, not designed to investigate
effectiveness, critical appraisal and synthesis of outcome findings of the included studies
were not carried out, and recommendations regarding their use cannot be made within the
scope of this review.
Cancer-related malnutrition is a complex condition attributable to the imbalance of
in vivo redox systems (including antioxidant enzymes and antioxidants) and upregulation
of proinflammatory cytokines [44,54]. Omega-3 has the ability to inhibit the production
of proinflammatory cytokines [48,49,63,65,71], and thus holds promise in its potential to
manage this syndrome [44,51,63,65]. Two previous systematic reviews (one in adults with
cancer undergoing chemotherapy and/or radiotherapy [84] and the other in adults with
cancer cachexia who were not undergoing cancer treatment during the study period [85])
indicated beneficial effects (e.g., improvements in body composition, weight, appetite, QoL)
of omega-3 fatty acid supplements (EPA; DHA). However, a systematic review in patients
with advanced cancer (which included locally recurrent cancers in definition) [86] did
not find sufficient evidence to support the superiority of omega-3 fatty acid supplements
(specifically EPA) over placebo. As the Cochrane review was conducted over 15 years ago,
it may be useful to conduct an updated review focusing on patients with metastatic cancer,
as more primary studies become available. This can also help identify the effectiveness
of dietary supplements in managing cancer-related malnutrition and address the lack of
Level 1 evidence in this population.
Overall, more primary studies are warranted for the dietary supplements elucidated
in this review. For example, carnitine was investigated in seven studies, of which only two
studies [41,53] investigated it as the sole intervention. Additionally, the present review has
mapped the types of dietary supplements to their proposed usefulness for particular cancer
types (i.e., vitamin D for prostate cancer). This may provide some indication to researchers
regarding the potentially efficacious dietary supplements that can be investigated in studies
for specific cancer types.
The strengths of this review include its methodological rigor in line with standards
and guidance for scoping review conduct and reporting, the dual approach to screening
and extraction to reduce error, and the comprehensive search strategy. Additionally, a wide
scope of all available evidence at varying levels on the evidence hierarchy was included. The
limitations of the present review include the exclusion of studies where dietary factors (e.g.,
vitamins, minerals, fatty acids) were administered via the intramuscular and intravenous
routes. These were excluded as they were technically not dietary supplements [87]; however,
they might have otherwise provided additional useful information. Additionally, while
efforts were made to contact study authors where missing information precludes the
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inclusion of a paper, only a small number of replies (5/38) were received. Lastly, as none of
the included studies specified the inclusion of children, sarcopenic, or frail populations, the
present review is unable to provide information on these population groups.
Implications for Research
With the identified dietary supplements and their noteworthy mechanisms and rationale for use in patients with metastatic cancers, particularly for omega-3, vitamin D,
and amino acids (arginine, carnitine, glutamine, and HMB), future research in this area is
required to assess efficacy on patient outcomes. Future studies should consider conducting
fully powered RCTs to increase the reliability of the results. With most of the existing
studies having been conducted among mixed or unspecified cancer populations, it would
be worthwhile to investigate the efficacy of dietary supplements in specific cancer types,
particularly in cancers where malnutrition-related issues are more prevalent (e.g., head
and neck cancers). As the forms of dietary supplements were considered to make a difference in some cases (i.e., purported superiority of phospholipids-bound omega-3 over
triacylglycerols-bound), researchers may consider the merit of the different forms of dietary
supplements when designing future studies. There is also a need to report malnutrition
with validated nutritional assessment tools (e.g., PG-SGA) in specific cancer cohorts (e.g.,
breast, lung, brain).
5. Conclusions
Dietary supplements investigated in studies conducted among patients with metastatic
cancers were multifarious and differed across cancer types. With plausible effects and
mechanisms proposed in relation to their role in managing malnutrition-related conditions
in this population group, future studies assessing the efficacy of dietary supplements on
patient outcomes are needed. As primary trials are still lacking for most of the dietary
supplements, future RCTs can be considered, along with a consideration of the forms of
dietary supplements to be tested, concomitant interventions to be employed (if any), and
the relevance of dietary supplements to the specific cancer type of interest.
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